MCID: RTN003
MIFTS: 50

Retinal Ischemia

Categories: Blood diseases, Cardiovascular diseases, Eye diseases

Aliases & Classifications for Retinal Ischemia

MalaCards integrated aliases for Retinal Ischemia:

Name: Retinal Ischemia 12 54 15 37 71

Classifications:



External Ids:

Disease Ontology 12 DOID:12510
ICD9CM 34 362.84
SNOMED-CT 67 26468004
ICD10 32 H35.82
UMLS 71 C0162291

Summaries for Retinal Ischemia

Disease Ontology : 12 An ischemia that is characterized by restriction in blood supply to the retina.

MalaCards based summary : Retinal Ischemia is related to exudative vitreoretinopathy 1 and ischemia. An important gene associated with Retinal Ischemia is HIF1A (Hypoxia Inducible Factor 1 Subunit Alpha), and among its related pathways/superpathways are ERK Signaling and Cellular Senescence (REACTOME). The drugs Bevacizumab and Ranibizumab have been mentioned in the context of this disorder. Affiliated tissues include retina, endothelial and eye, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Wikipedia : 74 Ocular ischemic syndrome is the constellation of ocular signs and symptoms secondary to severe, chronic... more...

Related Diseases for Retinal Ischemia

Diseases related to Retinal Ischemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 203)
# Related Disease Score Top Affiliating Genes
1 exudative vitreoretinopathy 1 32.3 VEGFA TNF HIF1A CRYAA CASP3
2 ischemia 30.9 VEGFA SOD1 KNG1 HSPA4 HIF1A CXCL12
3 retinal vein occlusion 30.9 VEGFA TNF CXCL12
4 microvascular complications of diabetes 5 30.7 VEGFA SOD1 HIF1A CXCL12 CRYAA
5 microvascular complications of diabetes 1 30.6 VEGFA HIF1A CXCL12
6 retinal vascular disease 30.4 VEGFA TXN TNF CRYAA CASP3
7 eales disease 30.1 VEGFA TNF SOD1
8 macular degeneration, age-related, 1 30.1 VEGFA TNF CRYAA CAT CASP3
9 optic nerve disease 30.0 VEGFA TNF POU4F1 CRYAA
10 intraocular pressure quantitative trait locus 29.9 VEGFA POU4F1 HSPB1 CRYAA
11 endophthalmitis 29.9 VEGFA TNF CRYAA
12 ocular hypertension 29.9 POU4F1 CXCL12 CRYAA
13 nonarteritic anterior ischemic optic neuropathy 29.7 VEGFA POU4F1 CASP2
14 vascular disease 29.7 VEGFA TNF SOD1 KNG1 HSPA4 CXCL12
15 t-cell leukemia 29.6 TNF NFKB1 CASP3 BCL2L1 BAX
16 myeloma, multiple 29.3 VEGFA TNF NFKB1 HSPA4 CXCL12 CASP3
17 eye disease 29.0 VEGFA TNF POU4F1 IGFBP2 HSPB1 CRYAA
18 cataract 28.9 VEGFA TXN TNF SOD1 HSPB1 CRYAA
19 neuroblastoma 28.3 VEGFA TNF SOD1 KNG1 HSPA4 HIF1A
20 exudative vitreoretinopathy 2, x-linked 11.2
21 exudative vitreoretinopathy 4 11.2
22 exudative vitreoretinopathy 3 11.2
23 meningitis and encephalitis 10.6 SOD1 CAT
24 indolent b-cell non-hodgkin lymphoma 10.5 BCL2L1 BAX
25 kashin-beck disease 10.5 TNF BAX
26 intravascular papillary endothelial hyperplasia 10.5 VEGFA HIF1A
27 bursitis 10.5 TNF KNG1 CXCL12
28 erysipelas 10.4 TNF SOD1 CAT
29 progressive multifocal leukoencephalopathy 10.4 TNF HIF1A BAX
30 spotted fever 10.4 TNF CASP3 BAX
31 prostatitis 10.4 TNF CAT CASP3
32 dystrophinopathies 10.4 TNF CASP2 APAF1
33 newcastle disease 10.4 TNF CASP3 BAX
34 iron deficiency anemia 10.4 TNF HIF1A CAT
35 oral lichen planus 10.4 HSPA4 CASP3 BAX
36 aseptic meningitis 10.4 TNF SOD1 CAT
37 tonsillitis 10.4 TNF SOD1 CASP3
38 myocardial stunning 10.4 SOD1 KNG1 CAT
39 cytomegalovirus infection 10.4 TNF NFKB1 CASP3
40 aids dementia complex 10.4 TNF CXCL12
41 lymphangiosarcoma 10.4 VEGFA TNF
42 branch retinal artery occlusion 10.4
43 retinal artery occlusion 10.4
44 varicocele 10.4 SOD1 HIF1A CAT CASP3
45 pneumoconiosis 10.3 TNF SOD1 CAT CASP3
46 yemenite deaf-blind hypopigmentation syndrome 10.3
47 retinal disease 10.3
48 peptic ulcer disease 10.3 TNF NFKB1 CAT
49 colon adenoma 10.3 VEGFA HIF1A CASP3
50 age-related hearing loss 10.3 SETD2 HIF1A

Comorbidity relations with Retinal Ischemia via Phenotypic Disease Network (PDN):


Hypertension, Essential

Graphical network of the top 20 diseases related to Retinal Ischemia:



Diseases related to Retinal Ischemia

Symptoms & Phenotypes for Retinal Ischemia

GenomeRNAi Phenotypes related to Retinal Ischemia according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.83 APAF1 BAX BCL2L1 CASP3 HIF1A NFKB1
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.83 APAF1 BAX BCL2L1 CASP3 HIF1A NFKB1
3 Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) GR00104-A-0 9.26 CASP2 CASP3 CAT TNF

MGI Mouse Phenotypes related to Retinal Ischemia:

45 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.37 APAF1 BAX BCL2L1 CASP2 CASP3 CAT
2 behavior/neurological MP:0005386 10.34 APAF1 BAX BCL2L1 CASP3 HIF1A HSPA4
3 hematopoietic system MP:0005397 10.22 BAX BCL2L1 CASP2 CASP3 CXCL12 HIF1A
4 mortality/aging MP:0010768 10.22 APAF1 BAX BCL2L1 CASP2 CASP3 CAT
5 cardiovascular system MP:0005385 10.21 APAF1 CASP3 CXCL12 HIF1A HSPB1 IGFBP2
6 growth/size/body region MP:0005378 10.21 APAF1 BAX BCL2L1 CASP3 HIF1A HSPB1
7 immune system MP:0005387 10.21 APAF1 BAX BCL2L1 CASP2 CASP3 CXCL12
8 endocrine/exocrine gland MP:0005379 10.2 APAF1 BAX BCL2L1 CASP2 CASP3 HIF1A
9 craniofacial MP:0005382 10.02 APAF1 CASP3 HIF1A NFKB1 SETD2 TNF
10 muscle MP:0005369 9.86 BAX CASP3 CXCL12 HIF1A NFKB1 SOD1
11 neoplasm MP:0002006 9.81 APAF1 BAX BCL2L1 CAT HIF1A SETD2
12 nervous system MP:0003631 9.8 APAF1 BAX BCL2L1 CASP2 CASP3 CXCL12
13 reproductive system MP:0005389 9.32 APAF1 BAX BCL2L1 CASP2 CASP3 CXCL12

Drugs & Therapeutics for Retinal Ischemia

Drugs for Retinal Ischemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 56)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 4 216974-75-3
2
Ranibizumab Approved Phase 4 347396-82-1 459903
3 Antineoplastic Agents, Immunological Phase 4
4 Angiogenesis Inhibitors Phase 4
5
Aspirin Approved, Vet_approved Phase 2, Phase 3 50-78-2 2244
6
Clopidogrel Approved Phase 2, Phase 3 120202-66-6, 113665-84-2 60606
7
Zinc Approved, Investigational Phase 2, Phase 3 7440-66-6 32051
8
Insulin aspart Approved Phase 2, Phase 3 116094-23-6 16132418
9 Platelet Aggregation Inhibitors Phase 2, Phase 3
10 Fibrinolytic Agents Phase 2, Phase 3
11 Anti-Inflammatory Agents Phase 2, Phase 3
12 Analgesics, Non-Narcotic Phase 2, Phase 3
13 Anti-Inflammatory Agents, Non-Steroidal Phase 2, Phase 3
14 Neurotransmitter Agents Phase 2, Phase 3
15 Antipyretics Phase 2, Phase 3
16 Cyclooxygenase Inhibitors Phase 2, Phase 3
17 Antirheumatic Agents Phase 2, Phase 3
18 Analgesics Phase 2, Phase 3
19 Purinergic P2Y Receptor Antagonists Phase 2, Phase 3
20 insulin Phase 2, Phase 3
21 Hypoglycemic Agents Phase 2, Phase 3
22 Insulin, Globin Zinc Phase 2, Phase 3
23
Triamcinolone Approved, Vet_approved Phase 2 124-94-7 31307
24
Methylprednisolone Approved, Vet_approved Phase 1, Phase 2 83-43-2 6741
25
Prednisolone Approved, Vet_approved Phase 1, Phase 2 50-24-8 5755
26
Methylprednisolone hemisuccinate Approved Phase 1, Phase 2 2921-57-5
27 Prednisolone acetate Approved, Vet_approved Phase 1, Phase 2 52-21-1
28
Prednisolone phosphate Approved, Vet_approved Phase 1, Phase 2 302-25-0
29
Prednisolone hemisuccinate Experimental Phase 1, Phase 2 2920-86-7
30 Immunologic Factors Phase 2
31 Triamcinolone diacetate Phase 2
32 Hormone Antagonists Phase 1, Phase 2
33 triamcinolone acetonide Phase 2
34 Immunosuppressive Agents Phase 2
35 glucocorticoids Phase 1, Phase 2
36 Triamcinolone hexacetonide Phase 2
37 Hormones Phase 1, Phase 2
38 Antiemetics Phase 1, Phase 2
39 Methylprednisolone Acetate Phase 1, Phase 2
40 Gastrointestinal Agents Phase 1, Phase 2
41 Epoetin alfa Phase 1, Phase 2 113427-24-0
42 Neuroprotective Agents Phase 1, Phase 2
43 Hematinics Phase 1, Phase 2
44 Antineoplastic Agents, Hormonal Phase 1, Phase 2
45 Autonomic Agents Phase 1, Phase 2
46 Protective Agents Phase 1, Phase 2
47
Propofol Approved, Investigational, Vet_approved 2078-54-8 4943
48
Sevoflurane Approved, Vet_approved 28523-86-6 5206
49 Hypnotics and Sedatives
50 Anesthetics

Interventional clinical trials:

(show all 41)
# Name Status NCT ID Phase Drugs
1 The Effect of Bevacizumab on Peripheral Retinal Changes as Imaged by Wide -Field Fluorescein Angiography in Diabetic Macular Edema Unknown status NCT02096874 Phase 4 Bevacizumab
2 Evaluation of the Effect of Repeated Intravitreal Injections of Anti-VEGF on Macular Perfusion in Diabetic Patients Using Optical Coherence Tomography Angiography Completed NCT03246152 Phase 4 Bevacizumab
3 Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Macular Edema in Subjects Who Completed the Three Year VISTA-DME Trial . Completed NCT02299336 Phase 4 Aflibercept
4 Prospective Trial of Treat and Extend Aflibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion: the PLATON Trial Recruiting NCT03405376 Phase 4 Intravitreal aflibercept injection
5 Normobaric Nocturnal Hyperoxia Therapy for Treating Ischemic-Related Retinal Conditions Enrolling by invitation NCT03730779 Phase 4 Hyperoxia
6 Different Regimens of Ranibizumab Treatment for Macular Edema Secondary to Retinal Vein Occlusion: a Randomized and Controlled Clinical Study. Not yet recruiting NCT04062370 Phase 4 Ranibizumab
7 The Carotid and Middle Cerebral Artery Occlusion Surgery Study Unknown status NCT01758614 Phase 3 Aspirin;Clopidogrel
8 Central Vein Occlusion Study (CVOS) Completed NCT00000131 Phase 3
9 Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks. Active, not recruiting NCT01969708 Phase 3 aflibercept;bevacizumab
10 Phase III Study of Pharos Vitesse Neurovascular Stent System Compared to Best Medical Therapy for the Treatment of Ischemic Disease Terminated NCT00816166 Phase 2, Phase 3 Aspirin and Clopidogrel (Medical therapy)
11 Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial Terminated NCT00991029 Phase 3 Clopidogrel;placebo
12 Effects of Pulsatile IV Insulin Delivery on Diabetic Retinopathy Terminated NCT00287651 Phase 2, Phase 3
13 Prevention of Retinal Non-perfusion in Central Retinal Vein Occlusion by Hydroxycarbamide Treatment. Unknown status NCT02957760 Phase 2 Hydroxycarbamid
14 The Efficacy of Intravitreal Aflibercept Injection in Improvement of Retinal Nonperfusion in Patients With Diabetic Retinopathy Unknown status NCT03006081 Phase 2 Intravitreal Aflibercept injection
15 Intravitreal Avastin Versus Intravitreal Avastin and Triamcinolone in Central Retinal Vein Occlusion(CRVO) Unknown status NCT00370630 Phase 2 Avastin (Bevacizumab) and triamcinolone
16 Ranibizumab Supplementing Panretinal Photocoagulation as Treatment for Iris/Angle Neovascularization in Retinal Ischemic Disease Completed NCT00841373 Phase 1, Phase 2
17 Study of Visual Recovery After Erythropoietin (EPO) Injection, in Patients With Traumatic Optic Neuropathy (TON) Completed NCT01783847 Phase 1, Phase 2 Recombinant human erythropoietin (EPO);Methyl prednisolone
18 Ranibizumab (rhuFab V2) and Scatter Laser Photocoagulation in Treatment of Patients With Clinically-significant Diabetic Macular Edema With Peripheral Retinal Nonperfusion (RaScaL) Completed NCT00815360 Phase 2 intravitreal injection of ranibizumab;intravitreal injection of triamcinolone acetonide
19 Phase I/II Randomized, Prospective, Double-masked, Sham-controlled Study of Intravitreal Autologous Bone Marrow CD34+ Stem Cell Therapy for Central Retinal Vein Occlusion Recruiting NCT03981549 Phase 1, Phase 2
20 Phase 2 Study of Safety and Efficacy of Aflibercept in Proliferative Diabetic Retinopathy. Active, not recruiting NCT02151695 Phase 2 Aflibercept intravitreal injections
21 A Randomized, Active-Controlled, Phase II Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation in Subjects With Radiation Retinopathy (RRR Study). Active, not recruiting NCT02222610 Phase 2 0.5 mg ranibizumab
22 Intravitreal Aflibercept for Retinal Non-Perfusion in Proliferative Diabetic Retinopathy Active, not recruiting NCT02863354 Phase 2 Aflibercept
23 Randomized Controlled Trial of Lucentis in the Management of New Onset Neovascular Glaucoma Withdrawn NCT00727038 Phase 1, Phase 2 Ranibizumab (Lucentis)
24 Correlation Between Retinal Metabolism and the Observation of a Visible Retinal Spontaneous Venous Pulse Unknown status NCT01794442
25 Objective Measurement of Retinal Ischemia in Central Retinal Vein Occlusion, and the Effects of Treatment With a Vascular Endothelial Growth Factor Inhibitor. Completed NCT01360385
26 Changes in the Diameter of Retinal Vessels After Remote Ischemic Conditioning in Patients With Type 1 Diabetes Completed NCT03906383
27 Evaluation of Heidelberg Engineering SPECTRALIS With OCT Angiography Module Completed NCT03279939
28 The Effects of Sevoflurane and Propofol on Light Flashed Evoked Pupillometry Completed NCT01219569 propofol;Sevoflurane
29 Prevalence and Characterization of Retinopathy in Children With Type 1 Diabetes Using a Non-mydriatic Fundus Camera Completed NCT02691312
30 Validation of Retinal Oximetry in Glaucoma Patients: a Structural and Functional Correlation Completed NCT01391247
31 Developing a Non-invasive Method and Device for Assessing the Degree of Midperipheral Retinal Ischemia in Diabetic Retinopathy. Completed NCT01546766
32 Costs and Outcomes of an Emergency Department-based Accelerated Diagnostic Protocol vs Hospitalization for Patients With Transient Ischemic Attack: a Randomized Controlled Trial. Completed NCT00321022
33 Short Term Ocular Safety Assessment of High Dose Omega-3 Supplementation for Age-Related Macular Degeneration. Completed NCT01258335
34 Triple Procedure for Dense Cataractus Neovascular Glaucoma Patients Completed NCT04143620
35 Pilot Study OCT of Retinal Blood Flow in Proliferative Diabetic Retinopathy Before and After Panretinal Photocoagulation Completed NCT01928550
36 The Individually-Marked Panretinal Laser phoTocoagulation for Proliferative Diabetic Retinopathy Study: IMPETUS 2018 - TREAT Completed NCT03113006
37 Spectral-domain Optical Coherence Tomography Findings in Retinal Vessel Occlusion - A Pilot Study of Detecting Ischemia in OCT Recruiting NCT03061526
38 Ultra-wide Fluorescein angiograpHy to Evaluate the Progression of Retinal ischeMia After aflibErcept Injections in patientS With Central Retinal Vein Occlusion in Real Life (HERMES Study) Recruiting NCT02880644
39 Correlation Between Macular Ischemia and Peripheral Ischemia in Patients With Diabetes Recruiting NCT02876744
40 Wide-Field and Projection-Resolved Optical Coherence Tomography Angiography in Diabetic Retinopathy Recruiting NCT03922932
41 Evaluation of the Repeatability and Reproducibility of OCTA Image Quality With the Heidelberg Engineering SPECTRALIS With OCT Angiography Module Terminated NCT03530449

Search NIH Clinical Center for Retinal Ischemia

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Retinal Ischemia cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Retinal Ischemia:
Bone marrow-derived stem cells for retinal diseases
Embryonic/Adult Cultured Cells Related to Retinal Ischemia:
Bone marrow-derived mononuclear cells (family) PMIDs: 21225138 23000646 19347139 23049424

Genetic Tests for Retinal Ischemia

Anatomical Context for Retinal Ischemia

MalaCards organs/tissues related to Retinal Ischemia:

40
Retina, Endothelial, Eye, Bone, Brain, T Cells, Heart

Publications for Retinal Ischemia

Articles related to Retinal Ischemia:

(show top 50) (show all 1523)
# Title Authors PMID Year
1
Pleiotropic effects of YC-1 selectively inhibit pathological retinal neovascularization and promote physiological revascularization in a mouse model of oxygen-induced retinopathy. 54 61
20008515 2010
2
Aqueous humor levels of vasoactive molecules correlate with vitreous levels and macular edema in central retinal vein occlusion. 54 61
19967679 2010
3
Insulin may cause deterioration of proliferative diabetic retinopathy. 54 61
19027244 2009
4
[Effects of recombinant human erythropoietin on hypoxia inducible factor-1alpha expression in the retina of rabbits with acute high intraocular pressure]. 54 61
19246297 2009
5
Vitreous levels of interleukin-6 and vascular endothelial growth factor in macular edema with central retinal vein occlusion. 54 61
19118700 2009
6
Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. 54 61
17591953 2007
7
Hsp27 upregulation by HIF-1 signaling offers protection against retinal ischemia in rats. 54 61
15728570 2005
8
Activation of vascular endothelial growth factor receptor-1 sustains angiogenesis and Bcl-2 expression via the phosphatidylinositol 3-kinase pathway in endothelial cells. 54 61
14633857 2003
9
Hypoxia-inducible factor 1: control of oxygen homeostasis in health and disease. 54 61
11328942 2001
10
Concentration of vascular endothelial growth factor in the subretinal fluid of retinal detachment. 54 61
11110038 2000
11
VEGF increases retinal vascular ICAM-1 expression in vivo. 54 61
10393052 1999
12
Vascular endothelial growth factor upregulation in human central retinal vein occlusion. 54 61
9499769 1998
13
Growth factor alterations in advanced diabetic retinopathy: a possible role of blood retina barrier breakdown. 54 61
9285495 1997
14
Upregulation of vascular endothelial growth factor in ischemic and non-ischemic human and experimental retinal disease. 54 61
9046048 1997
15
Analysis of localization of adult T-cell leukemia-derived factor in the transient ischemic rat retina after treatment with OP-1206 alpha-CD, a prostaglandin E1 analogue. 54 61
9010470 1997
16
Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. 54 61
8942877 1996
17
Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. 54 61
7479819 1995
18
Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. 54 61
7540233 1995
19
Hypoxic induction of endothelial cell growth factors in retinal cells: identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen. 54 61
8529097 1995
20
Mitochondrial induction of adult T cell leukemia derived factor (ADF/hTx) after oxidative stresses in retinal pigment epithelial cells. 54 61
8206709 1994
21
Vitreous levels of the insulin-like growth factors I and II, and the insulin-like growth factor binding proteins 2 and 3, increase in neovascular eye disease. Studies in nondiabetic and diabetic subjects. 54 61
7504689 1993
22
Stroke gets in your eyes: stroke-induced retinal ischemia and the potential of stem cell therapy. 61
31823871 2020
23
The effects of hyperbaric oxygen therapy on diabetic retinopathy: A preliminary study. 61
31831276 2020
24
SIRT1 is required for the neuroprotection of resveratrol on retinal ganglion cells after retinal ischemia-reperfusion injury in mice. 61
31900639 2020
25
Demonstration of acute retinal ischemia on diffusion weighted magnetic resonance imaging. 61
31816539 2020
26
Light-induced amaurosis - a case report and brief literature review. 61
32027984 2020
27
Site of Origin of the Ophthalmic Artery Influences the Risk for Retinal Versus Cerebral Embolic Events. 61
31985565 2020
28
LncRNA H19 initiates microglial pyroptosis and neuronal death in retinal ischemia/reperfusion injury. 61
31127201 2020
29
The "Use It or Lose It" Dogma in the Retina: Visual Stimulation Promotes Protection Against Retinal Ischemia. 61
31376070 2020
30
Inhibition of the Keap1-Nrf2 protein-protein interaction protects retinal cells and ameliorates retinal ischemia-reperfusion injury. 61
31669760 2020
31
Retinal ischemia due to extramedullary plasmacytomas of the orbit. 61
31982273 2020
32
Xanthophyll: Health benefits and therapeutic insights. 61
31783054 2020
33
NOD-like Receptors in the Eye: Uncovering Its Role in Diabetic Retinopathy. 61
32019187 2020
34
[Role of OCT-angiography in the management of sickle cell retinopathy]. 61
31831271 2020
35
Beneficial actions of prothymosin alpha-mimetic hexapeptide on central post-stroke pain, reduced social activity, learning-deficit and depression following cerebral ischemia in mice. 61
31982448 2020
36
Hexapeptide derived from prothymosin alpha attenuates cisplatin-induced acute kidney injury. 61
31912273 2020
37
[Mechanism of microglia promoting retinal ganglion cell death in vitro]. 61
31937061 2020
38
Differential sensitivity of the On and Off visual responses to retinal ischemia. 61
31899251 2019
39
Histone Deacetylases Contribute to Excitotoxicity-Triggered Degeneration of Retinal Ganglion Cells In Vivo. 61
31161423 2019
40
INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR FOR THE MANAGEMENT OF NEOVASCULARIZATION IN RETINOBLASTOMA AFTER INTRAVENOUS AND/OR INTRAARTERIAL CHEMOTHERAPY: Long-Term Outcomes in a Series of 35 Eyes. 61
30312257 2019
41
Neuroprotective Effect of Brazilian Green Propolis on Retinal Ganglion Cells in Ischemic Mouse Retina. 61
31842625 2019
42
Non-arteritic anterior ischemic optic neuropathy with Cilioretinal artery occlusion: a case report. 61
31726996 2019
43
Aldosterone as a mediator of severity in retinal vascular disease: Evidence and potential mechanisms. 61
31479654 2019
44
Serum erythropoietin concentration and its correlation with stage of diabetic retinopathy. 61
31727007 2019
45
One-year follow-up of ischemic index changes after intravitreal dexamethasone implant for diabetic macular edema: an ultra-widefield fluorescein angiography study. 61
31749052 2019
46
Tetrahedral framework nucleic acids prevent retina ischemia-reperfusion injury from oxidative stress via activating the Akt/Nrf2 pathway. 61
31642452 2019
47
Highlight article: The brain and eye: Treating cerebral and retinal ischemia through mitochondrial transfer. 61
31604382 2019
48
Regional Expression of Act-MMP3 Contributes to the Selective Loss of Neurons in Ganglion Cell Layers following Acute Retinal ischemia/Reperfusion Injury. 61
31661993 2019
49
Histological validation of per-bundle water diffusion metrics within a region of fiber crossing following axonal degeneration. 61
31326575 2019
50
Cell-Type-Specific Complement Expression in the Healthy and Diseased Retina. 61
31775049 2019

Variations for Retinal Ischemia

Expression for Retinal Ischemia

Search GEO for disease gene expression data for Retinal Ischemia.

Pathways for Retinal Ischemia

Pathways related to Retinal Ischemia according to GeneCards Suite gene sharing:

(show top 50) (show all 79)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.87 VEGFA TNF NFKB1 HIF1A CXCL12 CASP3
2
Show member pathways
13.17 VEGFA TXN SOD1 NFKB1 HSPA4 HIF1A
3
Show member pathways
13.16 TNF NFKB1 KNG1 CASP3 BAX APAF1
4
Show member pathways
13.03 VEGFA TNF NFKB1 CASP3 BCL2L1 BAX
5
Show member pathways
12.93 VEGFA TNF NFKB1 HIF1A CXCL12 CASP3
6
Show member pathways
12.91 VEGFA TXN TNF NFKB1 CASP3 CASP2
7
Show member pathways
12.88 VEGFA TNF HSPA4 CXCL12 CASP3 APAF1
8
Show member pathways
12.84 TNF NFKB1 CASP3 BCL2L1 BAX APAF1
9 12.82 TNF NFKB1 CASP3 BCL2L1 BAX APAF1
10 12.78 VEGFA TNF NFKB1 HSPB1 CASP3 CASP2
11
Show member pathways
12.76 NFKB1 CASP3 BCL2L1 BAX APAF1
12
Show member pathways
12.74 TNF NFKB1 HSPB1 CASP3 CASP2 BCL2L1
13
Show member pathways
12.71 TNF NFKB1 CASP3 CASP2 APAF1
14
Show member pathways
12.71 HSPB1 HSPA4 CASP3 CASP2 BAX APAF1
15 12.7 VEGFA NFKB1 KNG1 HIF1A CXCL12 CASP3
16
Show member pathways
12.66 VEGFA NFKB1 HIF1A BCL2L1 BAX
17
Show member pathways
12.62 VEGFA TNF NFKB1 HSPB1 BCL2L1
18
Show member pathways
12.48 NFKB1 CASP3 BCL2L1 BAX
19
Show member pathways
12.43 NFKB1 IGFBP2 BCL2L1 BAX
20 12.42 TNF NFKB1 BCL2L1 BAX
21
Show member pathways
12.41 CASP3 BCL2L1 BAX APAF1
22 12.38 TNF NFKB1 BCL2L1 BAX
23
Show member pathways
12.35 TXN TNF SOD1 NFKB1 CAT
24 12.34 VEGFA TNF HIF1A CASP3
25 12.34 TNF NFKB1 CASP3 BAX
26
Show member pathways
12.3 TNF NFKB1 CASP3 BCL2L1
27 12.28 TXN TNF NFKB1 BCL2L1
28
Show member pathways
12.28 HIF1A CASP3 CASP2 BCL2L1 BAX
29
Show member pathways
12.25 VEGFA NFKB1 HIF1A CASP3
30 12.24 TNF NFKB1 CASP3 BAX APAF1
31 12.19 VEGFA NFKB1 CASP3 BAX
32
Show member pathways
12.18 NFKB1 CASP3 BAX APAF1
33
Show member pathways
12.18 SOD1 NFKB1 CAT BAX
34 12.18 VEGFA TNF NFKB1 HIF1A CASP3
35 12.15 VEGFA TNF NFKB1 CASP3 BCL2L1 BAX
36
Show member pathways
12.14 TNF HSPB1 CASP3 CASP2 BAX APAF1
37 12.13 VEGFA TXN TNF NFKB1
38
Show member pathways
12.07 CASP3 BCL2L1 BAX APAF1
39 12.05 TNF NFKB1 KNG1 BAX
40
Show member pathways
12.05 TNF NFKB1 CASP3 CASP2 BAX
41 12.01 VEGFA TNF HIF1A BCL2L1
42 11.97 TXN TNF CASP3 CASP2 BCL2L1 BAX
43 11.95 TNF NFKB1 CXCL12 BCL2L1
44 11.95 TNF NFKB1 HSPB1 CASP3
45 11.95 VEGFA TNF NFKB1 CASP3 BAX
46
Show member pathways
11.9 VEGFA HSPB1 HIF1A
47 11.87 NFKB1 CASP3 BCL2L1 BAX APAF1
48 11.85 CASP3 CASP2 APAF1
49
Show member pathways
11.81 NFKB1 CXCL12 CASP3 BAX APAF1
50 11.8 TNF NFKB1 CASP3

GO Terms for Retinal Ischemia

Cellular components related to Retinal Ischemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 10.22 TXN SOD1 NFKB1 HSPB1 HSPA4 HIF1A
2 nucleus GO:0005634 10.13 TXN SOD1 SETD2 POU4F1 NFKB1 HSPB1
3 extracellular space GO:0005615 10.03 VEGFA TNF SOD1 KNG1 IGFBP2 HSPB1
4 cytoplasm GO:0005737 10.03 VEGFA TXN SOD1 POU4F1 NFKB1 HSPB1
5 extracellular region GO:0005576 9.65 VEGFA TXN TNF SOD1 NFKB1 KNG1
6 axon cytoplasm GO:1904115 9.5 SOD1 HSPB1 HIF1A
7 Bcl-2 family protein complex GO:0097136 9.37 BCL2L1 BAX
8 extracellular exosome GO:0070062 9.32 TXN SOD1 KNG1 IGFBP2 HSPB1 HSPA4

Biological processes related to Retinal Ischemia according to GeneCards Suite gene sharing:

(show all 35)
# Name GO ID Score Top Affiliating Genes
1 apoptotic process GO:0006915 10.09 NFKB1 CASP3 CASP2 BCL2L1 BAX APAF1
2 cytokine-mediated signaling pathway GO:0019221 9.97 VEGFA TNF HIF1A CASP3 BCL2L1
3 negative regulation of gene expression GO:0010629 9.96 VEGFA TNF POU4F1 NFKB1 HIF1A
4 aging GO:0007568 9.91 SOD1 IGFBP2 CAT CASP2 APAF1
5 negative regulation of neuron apoptotic process GO:0043524 9.88 SOD1 POU4F1 HIF1A BCL2L1 BAX
6 kidney development GO:0001822 9.85 VEGFA CAT BAX APAF1
7 response to organic substance GO:0010033 9.84 TNF SOD1 CASP3
8 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.84 TNF BAX APAF1
9 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.83 VEGFA TXN TNF
10 positive regulation of endothelial cell proliferation GO:0001938 9.83 VEGFA HIF1A CXCL12
11 response to virus GO:0009615 9.83 TNF HSPB1 CXCL12 BCL2L1
12 response to glucocorticoid GO:0051384 9.81 TNF IGFBP2 CASP3
13 positive regulation of neuron apoptotic process GO:0043525 9.8 TNF CASP3 CASP2 BAX
14 response to hydrogen peroxide GO:0042542 9.79 SOD1 CAT CASP3
15 positive regulation of cell adhesion GO:0045785 9.77 VEGFA TNF CXCL12
16 positive regulation of blood vessel endothelial cell migration GO:0043536 9.77 VEGFA HSPB1 HIF1A
17 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.76 TNF CASP2 BCL2L1 BAX
18 neuron apoptotic process GO:0051402 9.73 CASP3 BCL2L1 BAX APAF1
19 response to hypoxia GO:0001666 9.73 VEGFA HIF1A CXCL12 CAT CASP3 APAF1
20 regulation of mitochondrial membrane potential GO:0051881 9.71 SOD1 BCL2L1 BAX
21 ovarian follicle development GO:0001541 9.71 VEGFA SOD1 BCL2L1 BAX
22 response to radiation GO:0009314 9.67 TXN CXCL12 CAT BCL2L1
23 response to salt stress GO:0009651 9.65 TNF BAX
24 cellular response to nicotine GO:0071316 9.65 TNF NFKB1
25 myeloid cell homeostasis GO:0002262 9.64 SOD1 BAX
26 activation of cysteine-type endopeptidase activity involved in apoptotic process by cytochrome c GO:0008635 9.63 BAX APAF1
27 positive regulation of axon extension involved in axon guidance GO:0048842 9.63 VEGFA CXCL12
28 ectopic germ cell programmed cell death GO:0035234 9.62 CASP2 BAX
29 extrinsic apoptotic signaling pathway in absence of ligand GO:0097192 9.62 CASP3 CASP2 BCL2L1 BAX
30 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.61 VEGFA HIF1A
31 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.58 VEGFA HSPB1
32 luteolysis GO:0001554 9.58 CASP3 CASP2
33 positive regulation of apoptotic process GO:0043065 9.56 TNF SOD1 POU4F1 KNG1 CASP3 CASP2
34 apoptotic signaling pathway GO:0097190 9.55 TNF CASP3 CASP2 BAX APAF1
35 negative regulation of apoptotic process GO:0043066 9.36 VEGFA SOD1 POU4F1 NFKB1 HSPB1 HIF1A

Molecular functions related to Retinal Ischemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.28 VEGFA TXN TNF SOD1 SETD2 NFKB1
2 protein heterodimerization activity GO:0046982 9.77 VEGFA NFKB1 HIF1A BCL2L1 BAX
3 protein homodimerization activity GO:0042803 9.5 VEGFA SOD1 NFKB1 HSPB1 CAT BCL2L1
4 identical protein binding GO:0042802 9.36 VEGFA TNF SOD1 NFKB1 HSPB1 CRYAA
5 BH3 domain binding GO:0051434 9.26 BCL2L1 BAX
6 cysteine-type endopeptidase activity involved in execution phase of apoptosis GO:0097200 9.16 CASP3 CASP2

Sources for Retinal Ischemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....